Disease progression and pharmacodynamics in Parkinson disease - Evidence for functional protection with levodopa and other treatments

Nicholas H.G. Holford, Phylinda L.S. Chan, John G. Nutt, Karl Kieburtz, Ira Shoulson

Research output: Contribution to journalArticlepeer-review

67 Scopus citations

Abstract

We have modelled the Unified Parkinson's Disease Rating Scale (UPDRS) scores collected in 800 subjects followed for 8 years. Newly diagnosed and previously untreated subjects were initially randomized to treatment with placebo, deprenyl, tocopherol or both and, when clinical disability required, received one or more dopaminergic agents (levodopa (carbidopa / levodopa), bromocriptine, or pergolide). Using models for disease progression and pharmacodynamic models for drug effects we have characterized the changes in UPDRS over time to determine the influence of the various drug treatments. We have confirmed and quantitated the relative symptomatic benefits of the dopaminergic agents and provide model-based evidence for slowing of disease progression.

Original languageEnglish (US)
Pages (from-to)281-311
Number of pages31
JournalJournal of Pharmacokinetics and Pharmacodynamics
Volume33
Issue number3
DOIs
StatePublished - Jun 1 2006

Keywords

  • Bromocriptine
  • Deprenyl
  • Disease progression
  • Levodopa
  • Parkinson's disease
  • Pergolide
  • Pharmacodynamics

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Disease progression and pharmacodynamics in Parkinson disease - Evidence for functional protection with levodopa and other treatments'. Together they form a unique fingerprint.

Cite this